Geneva, March 23 -- International Clinical Trials Registry received information related to the study (ChiCTR2600120227) titled 'Safety and efficacy of ripertamab in patients with chronic inflammatory demyelinating polyneuropathy (RIPERT-CIDP): a randomised, double-blind, multicentre, placebo-controlled phase 3 trial' on March 11.
Study Type: Interventional study
Study Design:
Parallel
Primary Sponsor: Second Affiliated Hospital of Army Medical University
Condition:
chronic inflammatory demyelinating polyneuropathy
Intervention:
Treatment group:On Day 1 of the treatment period, an intravenous infusion of Ripertamab at a dose of 375 mg/m2 body surface area will be administered.
Recruitment Status: Not Recruiting
Phase: N/A
Date...